Today Illumina; tomorrow the world? Where the acquisition might really take Roche
This article was originally published in Scrip
Executive Summary
Hoffmann-La Roche wants to acquire the San Diego-based gene sequencing and array diagnostic company leader Illumina and the fact that it is willing to engage in a hostile takeover of the company and start the bidding in that process at a 64% premium to Illumina's most recent stock price indicated that the Swiss giant is really serious.
You may also be interested in...
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Stock Scan April 2018: Pharma's Fizz Falls Flat
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.